Trump not yet walking the walk on drug pricing in the USA

While US President Donald Trump has talked ardently and consistently about a desire to drastically reduce prescription drug prices, the omission of the CREATES Act from the recent US budget bill suggests his intentions don’t go much further than talking.

The Hill reports that, despite bipartisan support for the measures, Congress was not able to find room for them in the recently-signed budget deal.

CREATES would prevent drugmakers from abusing the Food and Drug Administration’s Risk Evaluation and Mitigation Strategies (REMS) program to thwart competition from generics rivals, a move supported by the agency’s Commissioner Scott Gottlieb.